SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2026
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc (the
'Company')
2026 Awards under the Deferred Investment Award
Programme
Notional Award
On 12 February 2026, the Company granted awards over notional
Ordinary Shares to Persons Discharging Managerial Responsibilities
('PDMRs') under the GlaxoSmithKline Deferred Investment
Award programme.
Under the programme, awards are made over notional Ordinary Shares
with vesting over a specified period to provide long-term alignment
with shareholders. Vesting is subject to the PDMR not having served
the Company notice or having been terminated by the Company for
cause. No dividends will accrue on the award during the vesting
period. On vesting, the award will be paid in cash. Executive
Directors are not eligible to receive awards under the
programme.
The awards have been granted to reward outstanding performance
during 2025 for two newly appointed Executive Committee members as
part of the Company's performance system for the general employee
population. The awards will vest on 12 February 2029.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Lynn Baxter
|
|
b)
|
Position/status
|
President, Europe
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.41
|
3,020
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mondher Mahjoubi
|
|
b)
|
Position/status
|
Chief Patient Officer
|
|
c)
|
Initial
notification/
amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
A restricted award of notional Ordinary Shares under the Company's
Deferred Investment Award programme.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
£21.41
|
3,020
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
|
e)
|
Date
of the transaction
|
2026-02-12
|
|
f)
|
Place
of the transaction
|
N/A
|
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
16, 2026
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|
